General MedicationsINTRAVENOUSStandard
BLOXIVERZ
NEOSTIGMINE METHYLSULFATE
Standard Dose
5MG/5ML (1MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview BLOXIVERZ is listed in Drugs@FDA under application 204078 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient NEOSTIGMINE METHYLSULFATE Form and strength SOLUTION;INTRAVENOUS - 5MG/5ML (1MG/ML) Sponsor EXELA PHARMA Submission history Latest submission status date: 2023-10-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview BLOXIVERZ is listed in Drugs@FDA under application 204078 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient NEOSTIGMINE METHYLSULFATE Form and strength SOLUTION;INTRAVENOUS - 5MG/5ML (1MG/ML) Sponsor EXELA PHARMA Submission history Latest submission status date: 2023-10-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.